| Literature DB >> 34250950 |
Manon Auffret1,2, Vincent Meuric3, Emile Boyer3, Martine Bonnaure-Mallet3, Marc Vérin1,2,4.
Abstract
Despite clinical evidence of poor oral health and hygiene in Parkinson's disease (PD) patients, the mouth is often overlooked by both patients and the medical community, who generally focus on motor or psychiatric disorders considered more burdensome. Yet, oral health is in a two-way relationship with overall health-a weakened status triggering a decline in the quality of life. Here, we aim at giving a comprehensive overview of oral health disorders in PD, while identifying their etiologies and consequences. The physical (abnormal posture, muscle tone, tremor, and dyskinesia), behavioral (cognitive and neuropsychiatric disorders), and iatrogenic patterns associated with PD have an overall detrimental effect on patients' oral health, putting them at risk for other disorders (infections, aspiration, pain, malnutrition), reducing their quality of life and increasing their isolation (anxiety, depression, communication issues). Interdisciplinary cooperation for prevention, management and follow-up strategies need to be implemented at an early stage to maintain and improve patients' overall comfort and condition. Recommendations for practice, including (non-)pharmacological management strategies are discussed, with an emphasis on the neurologists' role. Of interest, the oral cavity may become a valuable tool for diagnosis and prognosis in the near future (biomarkers). This overlooked but critical issue requires further attention and interdisciplinary research.Entities:
Keywords: Parkinson’s disease; dentistry; interdisciplinary research; microbiota; oral health; stomatognathic diseases
Mesh:
Year: 2021 PMID: 34250950 PMCID: PMC8609694 DOI: 10.3233/JPD-212605
Source DB: PubMed Journal: J Parkinsons Dis ISSN: 1877-7171 Impact factor: 5.568
Summary of the main findings found in international literature regarding oral health disorders in patients with Parkinson’s disease (orofacial symptoms, oral health, oral hygiene). For detailed results, please refer to Supplementary Table 1
| Reference/country | Methodology: Subjects, type of assessments and study design | Direct and indirect orofacial consequences of PD and PD medication | Main findings for patients with PD | ||
| Oral health disorders | Oral hygiene | Conclusion | |||
| Anastassiadou et al., 2002 [ | • | •Hypomimia, speech difficulties, facial muscles rigidity, facial tremor
| Periodontal diseases#, dental caries, erosion, denture problems, ulcer, hyperplasia, chewing (related to teeth or denture), | •Reduced
| •Orofacial, oral and dental disorders in PD
|
| Bakke et al., 2011 [ | • | •Impaired masticatory function | NA | NA | •Increased impairment masticatory function with PD severity |
| •Matched control subjects | •Drooling, reduced opening capacities | ||||
| •Objective & subjective assessments | |||||
| •Case control study | |||||
| Barbe et al., 2017 [ | • | •Snacking behavior
| NA | •Reduced
| •Increased impairment with PD duration |
| •No control group | |||||
| •Subjective assessments | |||||
| •Cross-sectional study | |||||
| Barbe et al., 2017 [ | • | •Altered taste sensation | •Periodontal diseases (periodontitis), halitosis | NA | •Impaired oral health-related quality of life |
| •Matched control subjects | •Xerostomia | ||||
| •Objective & subjective assessments | |||||
| •Case control study | |||||
| Cicciù et al., 2012 [ | • | •Discomfort with mouthwashes (fear of choking?) | •Periodontal diseases (periodontitis), mobile and missing teeth | •Reduced | •Poorer oral health in patients with PD |
| •Matched control subjects | |||||
| •Objective assessments & interview | |||||
| •Case control study | |||||
| Clifford & Finnerty, 1995 [ | • | •Xerostomia, dysphagia, burning mouth syndrome | •Periodontal disease (periodontitis), denture problems, ulcer, mobile teeth | •Reduced | •Oral health disorders
|
| •No control group | •Difficulties with dental appointment (anxiety, affordability, accessibility) | ||||
| •Subjective assessments (self-reporting, postal questionnaire) | |||||
| •Cross-sectional study | |||||
| Einarsdóttir et al., 2009 [ | • | •Difficulties with dental appointment (affordability, Patients and dentist reluctance?) | •Periodontal diseases (periodontitis), dental caries, missing teeth
| •Reduced | •Poorer oral health in patients with PD |
| •Control subjects (spouse or family member) | |||||
| •Objective & subjective assessments | |||||
| •Case control study | |||||
| Frota et al., 2016 [ | • | •Angular cheilitis | •Periodontal diseases (periodontitis), dental caries, denture problems, missing teeth, bruxism | NA | •No difference in oral disease between PD and AD group |
| •Control groups (healthy control and Alzheimer’s disease) | |||||
| •Objective assessments | |||||
| •Case control study | |||||
| Fukayo et al., 2003 [ | • | •Preference for soft food | NA | •Better | •Better dental status* |
| •Control group ( | |||||
| •Objective & subjective assessments | |||||
| •Case control study | |||||
| Hanaoka & Kashihara, 2009 [ | • | NA | •Periodontal diseases (periodontitis), dental caries, missing teeth | NA | •Higher oral health disorders even in early stage of PD |
| •Control groups age-matched (mild neurological disease and acute and ischemic stroke) | |||||
| •Case control study | |||||
| Kennedy et al., 1994 [ | • | •Xerostomia | •Mucositis
| NA | •More mucositis and higher counts in cariogenic bacteria in patient with PD |
| •Control group (age and sex, mean age = 64.1±6.8 y) | |||||
| •Objective assessments | |||||
| •Case control study | |||||
| Lyra et al., 2020 [ | • | •Xerostomia | •Periodontal diseases (periodontitis), mobile and missing teeth | •Reduced | •Association between PD progression (upper extremity rigidity, hand posture and tremor) and impaired oral hygiene habits and severity of periodontitis |
| •No control group | |||||
| •Objective & subjective assessments | |||||
| •Cross-sectional study | |||||
| Müller et al., 2011 [ | • | •Reduced salivary flow | •Periodontal diseases (periodontitis), dental caries, mobile teeth. | •Reduced | •Poorer oral health in patients with PD |
| •Unmatched control subjects | |||||
| •Objective & subjective assessments, including a blind assessment (clinical status/dental hygienist) | |||||
| •Case control study | |||||
| Nakayama et al., 2004 [ | • | •Dysphagia
| •Periodontal diseases (gingivitis), missing teeth, denture problem, chewing difficulties (related to teeth or denture) | •Reduced
| •Complain about oral health
|
| Persson et al., 1992 [ | • | •Dysphagia | NA | •Reduced | •Good oral health** |
| •Case control study | •Motor symptoms (impairment of motor skills) | •Difficulties in performing oral hygiene correlated to the severity of hypokinesia | |||
| •Objective & subjective assessments | |||||
| Pradeep et al., 2015 [ | • | NA | •Periodontal diseases (periodontitis) | •Reduced (deteriorating with PD severity) | •Deteriorating oral health in PD patients even at early stage (Hoehn and Yahr stage 1) |
| •Control group (age-matched familly member) | |||||
| •Objective (blinded) & subjective assessments | |||||
| •Case control study | |||||
| Ribeiro et al., 2016 [ | • | •Motor symptoms | NA | NA | •Negative perception of oral health but no objective difference (PD severity not recorded) |
| •Control group ( | |||||
| •Objective & subjective assessments | |||||
| •Case control study | |||||
| Schwarz et al., 2006 [ | • | •Motor symptoms (impairment of motor skills) | •Periodontal diseases (periodontitis) | •Reduced | •Periodontal diseases increased in patient with PD |
| •Control subjects, age-matched | |||||
| •Objective assessment | |||||
| •Case control study | |||||
| van Stiphout et al., 2018 [ | •N = 74, mean age 70.2±8.8 y, mean PD duration 9.1±6.4 y, | •Altered taste sensation
| •Periodontal diseases (periodontitis), dental caries, mobile teeth, chewing difficulties (related to teeth or denture) | •Reduced (deteriorating with PD severity) | •Weakened oral health status |
| •Objective & subjective assessments | Disease severity and duration were associated with more oral health and hygiene care problems | ||||
| •Case control study | |||||
LEDD, levodopa equivalent daily dose; PD, Parkinson’s disease; NA, not assessed. *Since the present study only deals with patients with mild symptoms, it should be noted that the results shown here may not be applicable to advanced PD patients. **Authors’ hypotheses: “general conscientiousness in patients and relatives”. # Periodontal disease account for gingivitis, periodontitis.
Fig. 1The direct and indirect impact of Parkinson’s disease on oral health and hygiene: contributing physical, psychological (blue boxes) and iatrogenic (red box) factors. (See online version for colour figure.)
Antiparkinsonian treatments and dentistry: potential local and general side effects and drug interactions [26, 69, 84–98, 225]
| Classification – Generic names | Relevant local (orofacial) and general side effects | Interactions with drugs used in dentistry |
|
| •Local: xerostomia, dry throat | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| Benztropine | •General: nausea/vomiting, loss of appetite, mental confusion, dizziness, depression | |
| Biperiden | ||
| Trihexyphenydil | ||
| •Local: dry mouth, subjective saliva thickening, oral microbiota changes neck pain | None reported at the time of our writing | |
| •General: swelling, pain, nausea, drowsiness, anxiety, difficulty falling asleep or staying asleep | ||
|
| ||
| Apomorphine | •Local: none reported at the time of our writing | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: orthostatic hypotension, nausea/vomiting, confusion | ||
| Bromocriptine | •Local: none reported at the time of our writing | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: nausea/vomiting, heartburn, stomach cramps, loss of appetite, orthostatic hypotension | ||
| Cabergoline | •Local: xerostomia, toothache, throat irritation | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: nausea/vomiting, heartburn, orthostatic hypotension, fatigue | ||
| Pergolide | •Local: xerostomia | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: orthostatic hypotension | ||
| Pramipexole | •Local: dry mouth | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: nausea, heartburn, orthostatic hypotension | ||
| Ropinirole | •Local: xerostomia, gingivitis, glossitis, tongue edema, toothache, pharyngitis | •Fluoroquinolones (CYP1A2 inhibitor → influence the elimination of ropinirole) |
| •General: nausea/vomiting, heartburn, stomach pain, orthostatic hypotension, sedation, loss of appetite/weight loss, anxiety | •Sedatives (e.g.: narcotic analgesics, antihistamines) | |
|
| ||
| Levodopa-carbidopa | •Local: xerostomia, dysgeusia, glossitis, parafunction ((awake) bruxism, clenching), glossodynia, “dark” saliva/teeth pigmentation, dysphagia, Burning mouth syndrome, mouth and throat pain, serpentine tongue, lingual protrusion dystonia, Meige’s syndrome | •Anesthetic agents containing epinephrine (blood pressure & heart rate)
|
| •General: orthostatic hypotension, nausea/vomiting, dyskinesia, loss of appetite/anorexia, forgetfulness or confusion | ||
| Levodopa-carbidopa- entacapone | •Local: xerostomia, dysgeusia, glossitis, parafunction ((awake) bruxism, clenching), glossodynia, “dark” saliva, teeth pigmentation, dysphagia, mouth and throat pain, dyskinesia
| •Anesthetic agents containing epinephrine (blood pressure & heart rate)
|
|
| ||
| Entacapone | •Local: none reported at the time of our writing
| •May potentiate the chronotropic and arrhythmogenic effects of isoproterenol and epinephrine
|
| Rasagiline | •Local: xerostomia, swollen gums
| •Meperidine hydrochloride (hyperthermia, hypertension, tachycardia) |
| •Fluoroquinolones (CYP1A2 inhibitor → influence the elimination of rasagiline) | ||
| •Pethidine (hyperthermia, delirium, muscle rigidity) | ||
| Selegiline | •Local: dysgueusia, bruxism, sublingual oral ulcerations, burning lips/mouth, facial grimacing, dry mouth, difficulty swallowing
| •Levonordefrin (severe hypertension)
|
| •Meperidine, propoxyphene (acute serotonin syndrome/ hypertensive crisis, seizures, and coma) | ||
| •Pethidine (hyperthermia, delirium, muscle rigidity) | ||
|
| ||
| Amantadine | •Local: xerostomia | Sedatives (e.g.: narcotic analgesics, antihistamines) |
| •General: nausea/vomiting, decreased appetite, orthostatic hypotension, mental confusion | ||
| •Surgical and device related: infections, mental status change | Diathermy, electrocautery (thermic neural lesion) | |
| •Stimulation-induced: neuropsychiatric disorders (depression), dysarthria (loss of verbal fluency), postural instability/gait disturbances |
Oral health disorders in parkinsonian patients: symptoms, etiologies, consequences (on local & general health) and available prevention and management strategies
| Symptom | Etiologies – Contributing factors | Consequences | Prevention and management strategies |
| Dysphagia [3,23,27,39,42–45,141,147,148,151,190,218,231–234] [3,21,38,39,41,43,44,47,139,142,145,148,153,173,174,226–230] | Prevalence: 35%subjective | •Increased risk of choking, aspiration and pneumonia
| •Eating habits: cut food into smaller pieces, alter texture and consistency to facilitate swallowing
|
| Hypomimia [25,26,31,42,118] | •DA deficiency
| •Impaired verbal & non-verbal communication
| •Speech therapy to enhance verbal communication (facial mobility) |
| Speech disorders [25,41,45,46,231,232] e.g.: dysarthria, hypophonia, slurred words, fast speech, or hesitation before speaking | Up to 89%of patients
| •Difficulties in communication
| •Speech therapy (voice modulation, volume, intonation, articulation)
|
| Altered taste sensation [5,61,64,138,144,233] (e.g., reduced food flavor, bad taste in the mouth) | Up to 27%•Drug-induced dysgeusia (levodopa, pergolide)
| •Decreased appetite, loss of interest in ingesting food, modification of food choices
| •Food changes (nausea)
|
| Xerostomia (subjective) Hyposalivation (objective) [5,18,26,69,80,81,86,115,233,234] | Up to 87%•Autonomic disorders
| •Reduces antibacterial and cleansing action of saliva and tongue → risk factor for oral diseases and lesions
| •Lubricating sprays (malic acid), physostigmine gels, saliva substitutes (particularly at meal times) & artificial salivary products (evidence grade B/moderate)
|
| Drooling [3,15,18,25,26,41,88,94,229,230,235–239] | Various prevalence depending on disease stage (10-84%), with diurnal (23-28%) & nocturnal (up to 58%) drooling
| •Dermatitis, angular cheilosis, skin irritation
| •Intrasalivary gland injection of botulinum toxin (BTX-A/B), every 3 months (evidence grade A, high)
|
| Bruxism [54,65,66,102,240] - Awake bruxism (AB) - Sleep bruxism (SB) | •Non-dopaminergic mechanisms
| •Attrition → teeth, implant and crowns breakage
| •Custom-made thermoplastic bruxism splint
|
| Mastication & temporomandibular disorders [5,26,49,51,54,108,115,136,227] | •Reduced muscle tone (jaw, tongue, lips, oropharynx)
| •Chewing disorders, impaired food intake, preference for softer food (→ malnutrition, weight loss)
| •Maintenance of natural teeth trough avoidance of dental disease & dental caries
|
| Reduced ability to perform oral hygiene [18,28,78,102,136] | •DA & non DA mechanisms
| •Increased risk of caries and periodontal diseases
| •Repeated instructions on proper brushing & flossing techniques
|
| Denture problems, poor denture retention [68,71,79,83,88,102,108,115,234,241] | •Muscle incoordination (tongue, lips, jaw) & inadequate amount of saliva (→ lack of denture control)
| •Discomfort, denture-related oral mucosal lesions: local/diffuse inflammation, hyperplasia, ulcers
| •Prosthetic rehabilitation and follow-up
|
| Increased number of caries [18,27,28,68,74,136,149,242] | •Cariogenic environment: changes in eating habits: craving for sweets, altered taste sensation & use of high-calorie dietary supplements
| •Discomfort (pain, sensitivity)
| •Fluoridated toothpaste 2500–5000 ppm & gels (evidence grade A, high)
|
| Increased prevalence and severity of periodontal diseases (gingivitis and periodontitis) [5,27,28,68,72–77,224] | •Reduced oral hygiene (plaque formation)
| •Discomfort (pain, sensitivity)
| •Restore and maintain appropriate oral hygiene
|
| Erosion, attrition & teeth breakage [27,28,74,78,108] | •Falls (postural hypotension, gait disorders)
| •Discomfort (pain, sensitivity)
| •Mouth guard
|
| Tooth loss [27,79,108] | •Caries & periodontal disease
| •Chewing disorders, eating difficulties and self-feeding impairment
| •Prosthetic rehabilitation and follow-up
|
| Burning mouth syndrome (BMS) [26,66,67,70,86,108,243,244] | Prevalence: 4–24%•DA receptors dysfunction
| •Discomfort, pain
| •Cognitive behavioral therapy, psychotherapy, behavioral feedback
|
AB, awake bruxism; BMS, burning mouth syndrome; BTX, botulinum toxin; CNS, central nervous system; DA, dopaminergic; L-dopa, levodopa; MAO-B, monoamine oxidase-B; PD, Parkinson’s disease; SB, sleep bruxism.
Fig. 4Addressing oral health disorders in Parkinson’s disease: An integrated care approach, coordinated by the movement disorders team (neurologist and PD nurse).
Prevention and management strategies at the dental office: advices from the neurologist to the dental team [3,18,21,26,68,78,79,86,102,106,108,115,136,245–248]
| Parkinson’s disease (PD) specificities | Prevention and management strategies | |
| General comments | •Education & training (i.e., PD rounds/students, courses/students & continuing medical education) to enhance PD knowledge and interdisciplinary cooperation | |
| •Consult with the neurologist to identify PD stage (cognitive status, disease prognosis) and drug regimens | ||
| •Tailor the appointments to patient’s specific condition (fluctuations and drug regimens) | ||
| •Advise: | ||
| –Oral hygiene/home care program with appropriate oral healthcare tools | ||
| –Symptom-relieving products (with the help of pharmacist if needed), | ||
| –Home training program | ||
| •Ensure repeated oral health education | ||
| Accessibility | •Ensure accessibility to the dental office (steps & lifts/cane, walker, wheelchair) | |
| •Provide assistance to get in and out of the dental chair (if needed) | ||
| Communication issues | •Identify the underlying type of issue | |
| •Cognitive disorders and dementia | •Face-to-face communication (eye contact) in a quiet room, with no or limited background noise | |
| •Reduced non-verbal communication | •Use visual aids and written materials if needed | |
| •Speech and language disorders | •Use closed-ended questions (yes/no), simple words & short sentences | |
| •Allow adequate time for the patient to respond (slower response rate) | ||
| •Allow caregiver’s presence beside next to the operating chair (may help interpreting the patient’s speech) -but do not ignore the patient by talking only to the caregiver | ||
| •Referral to speech and language therapy if needed | ||
| Medical/surgical interactions | •Take a detailed medical history before any dental treatment (overall health, allergies, medical diagnosis, up-to-date list of medications, history of any surgeries) | |
| •Consult with the neurologist/physician and pharmacist if needed | ||
| •In case of sedation, consider using a slower titration regime | ||
| •Look for a history of deep brain stimulation (DBS): diathermy and electrocautery may cause thermic neural lesion | ||
| Autonomic dysfunction | Postural hypotension | •If possible, vital signs (blood pressure, heart rate, pulse) measurements on every visit |
| •Provide assistance to get in and out of the dental chair (if needed) | ||
| •Allow adequate time for the patient to change position, raise the chair slowly to the upright position | ||
| Urinary incontinence | •Ensure that washrooms are accessible within the dental office | |
| •Advice patients to empty their bladder before beginning any dental procedure | ||
| Motor symptoms | Fluctuations | •Tailor the appointments to each patient condition |
| •Quiet room, stress-free environment | ||
| •Plan a series of brief office visits rather than few long visits (more realistic & more productive): short (<45 min), early or mid-morning appointments, 60–90 minutes after PD drugs intake (“Best ON”) | ||
| •Adjustment to the chair and interruption of dental treatment if needed (tremors, dyskinesia) | ||
| Dysphagia | •Dental chair inclined at 30–45 degrees to facilitate the swallowing (adjust if needed to avoid aspiration) | |
| •Use of dental rubber dam | ||
| •Adapt the use of the aspirator tip to patient’s saliva characteristics (quality, quantity) | ||
| •Allow regular breaks during treatment | ||
| •Tilt head to one side (pooling in cheek) | ||
| Reduced mouth opening | •Use of extraoral ratchet-type mouth prop and intraoral rubber bite block | |
| •Consult with the neurologist to adjust PD medication if needed (fluctuations) | ||
| •Home training program: jaw opening and lip and chewing exercises | ||
| Neuropsychiatric disorders | Anxiety, stress | •Self-identification, smile, direct eye contact and gentle touch |
| •Patients should always be treated by the same dentist | ||
| •Explain each step of the procedure before performing them | ||
| •Regularly reassure & consult the patient for any discomfort | ||
| •Allow caregiver’s presence beside next to the operating chair | ||
| •Good time management (avoid the sense of rushing) | ||
| •Use anxiety/stress (non-)pharmacological reduction techniques (if needed) | ||
| Cognitive deficits, dementia | •Make sure to get appropriate consent | |
| •Patients should always be treated by the same dentist. | ||
| •Compassionate, stress-free and caring environment. | ||
| •Use simple words & short sentences | ||
| •Allow caregiver’s presence beside next to the operating chair (stress, communication) | ||
| •Limit the use of face mask (stress/anxiety) | ||
| •Use the VERA framework for communication: | ||
| Aspiration during dental procedure | •Prevention: | |
| –Patients should not be treated in the supine position but in a more vertical position (≥30–45 degrees) | ||
| –Four-handed dentistry | ||
| –Use of rubber dental dams or (small) gauze screens (to protect the oropharynx) or use clasps with floss if needed (small-sized objects should be secured with dental floss to secure and aid retrieval) | ||
| –Aggressive oral suctioning (in case of dysphagia) | ||
| –Use smaller amounts of water and reduced flow during procedures | ||
| •Management: immediate emergency care, bronchoscopy | ||
DBS, deep brain surgery; PD, Parkinson’s disease.